TY - JOUR
T1 - Challenges and Future Directions in Redo Aortic Valve Reintervention after Transcatheter Aortic Valve Replacement Failure
AU - Zaid, Syed
AU - Bapat, Vinayak N.
AU - Sathananthan, Janarthanan
AU - Landes, Uri
AU - De Backer, Ole
AU - Tarantini, Giuseppe
AU - Grubb, Kendra J.
AU - Kaneko, Tsuyoshi
AU - Khalique, Omar K.
AU - Jilaihawi, Hasan
AU - Fukui, Miho
AU - Madhavan, Mahesh
AU - Cangut, Busra
AU - Harrington, Katherine
AU - Thourani, Vinod H.
AU - Makkar, Raj R.
AU - Leon, Martin B.
AU - Mack, Michael J.
AU - Tang, Gilbert H.L.
N1 - Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023/11/1
Y1 - 2023/11/1
N2 - Transcatheter aortic valve replacement (TAVR) is increasingly being performed in younger and lower surgical risk patients. Reintervention for failed transcatheter heart valves will likely increase in the future as younger patients are expected to outlive the initial bioprosthesis. While redo-TAVR has emerged as an attractive and less invasive alternative to surgical explantation (TAVR-explant) to treat transcatheter heart valve failure, it may not be feasible in all patients due to the risk of coronary obstruction and impaired coronary access. Conversely, TAVR-explant can be offered to most patients who are surgical candidates, but the reported outcomes have shown high mortality and morbidity. This review provides the latest evidence, current challenges, and future directions on redo-TAVR and TAVR-explant for transcatheter heart valve failure, to guide aortic valve reintervention and facilitate patients' lifetime management of aortic stenosis.
AB - Transcatheter aortic valve replacement (TAVR) is increasingly being performed in younger and lower surgical risk patients. Reintervention for failed transcatheter heart valves will likely increase in the future as younger patients are expected to outlive the initial bioprosthesis. While redo-TAVR has emerged as an attractive and less invasive alternative to surgical explantation (TAVR-explant) to treat transcatheter heart valve failure, it may not be feasible in all patients due to the risk of coronary obstruction and impaired coronary access. Conversely, TAVR-explant can be offered to most patients who are surgical candidates, but the reported outcomes have shown high mortality and morbidity. This review provides the latest evidence, current challenges, and future directions on redo-TAVR and TAVR-explant for transcatheter heart valve failure, to guide aortic valve reintervention and facilitate patients' lifetime management of aortic stenosis.
KW - aortic valve stenosis
KW - bioprosthesis
KW - transcatheter aortic valve replacement
UR - http://www.scopus.com/inward/record.url?scp=85177644461&partnerID=8YFLogxK
U2 - 10.1161/CIRCINTERVENTIONS.123.012966
DO - 10.1161/CIRCINTERVENTIONS.123.012966
M3 - Review article
C2 - 37988437
AN - SCOPUS:85177644461
SN - 1941-7640
VL - 16
SP - E012966
JO - Circulation: Cardiovascular Interventions
JF - Circulation: Cardiovascular Interventions
IS - 11
ER -